{"id":"inj-octreotide","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Cholelithiasis"},{"rate":null,"effect":"Injection site pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Octreotide mimics the natural hormone somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and vascular tissue. This binding suppresses the secretion of growth hormone, insulin, and other hormones, and reduces splanchnic blood flow. These effects make it useful in controlling hormone-related symptoms and slowing tumor growth in neuroendocrine malignancies.","oneSentence":"Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels, inhibiting the release of various hormones and reducing blood flow to tumors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:03.929Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly"},{"name":"Variceal bleeding in portal hypertension"},{"name":"Carcinoid syndrome"},{"name":"VIPoma"},{"name":"Gastrinoma"},{"name":"Neuroendocrine tumors"}]},"trialDetails":[{"nctId":"NCT02299089","phase":"PHASE2","title":"Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2015-01","conditions":"Acromegaly, Neuroendocrine Tumors","enrollment":12},{"nctId":"NCT01301222","phase":"PHASE4","title":"Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas","status":"COMPLETED","sponsor":"PVS Memorial Hospital","startDate":"2010-09","conditions":"Pancreatic Fistula","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inj Octride"],"phase":"marketed","status":"active","brandName":"Inj. Octreotide","genericName":"Inj. Octreotide","companyName":"PVS Memorial Hospital","companyId":"pvs-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels, inhibiting the release of various hormones and reducing blood flow to tumors. Used for Acromegaly, Variceal bleeding in portal hypertension, Carcinoid syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}